Literature DB >> 31596122

Comparison of monocyte with high density lipoprotein cholesterol ratio in dipper and nondipper hypertensive patients.

Murat Selcuk1, Ersin Yildirim2, Faysal Saylik1.   

Abstract

Aim: We aimed to compare the monocyte to HDL-cholesterol ratio (MHR) of nondipper hypertension (NDHT) and dipper hypertension patients. Patients & methods: A total of 162 patients were included in the study. Patients were grouped as dipper and nondipper according to 24-h ambulatory blood pressure recordings.
Results: The MHR was significantly higher in nondipper hypertension group compared with control (p < 0.001) and dipper hypertension groups (p = 0.03). MHR, hs-CRP and red-cell distribution width (RDW) were independent predictors of nondipper hypertension. Area under the curve was 0.62 (p = 0.034) for MHR and 0.61 (p = 0.012) for hs-CRP in the ROC analysis.
Conclusion: MHR has elevated levels in NDHT patients. Increased levels of MHR may evaluate as increased risk of cardiovascular events in NDHT patients.

Entities:  

Keywords:  HDL-cholesterol; dipper hypertension; hypertension; monocyte count; nondipper hypertension

Mesh:

Substances:

Year:  2019        PMID: 31596122     DOI: 10.2217/bmm-2019-0062

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  3 in total

1.  The Role of Monocyte to High-Density Lipoprotein Cholesterol Ratio in Predicting the Severity of Proteinuria and Renal Dysfunction in Primary Nephrotic Syndrome.

Authors:  Fatma Yılmaz Aydın; Eren Eynel; İdris Oruç; Hasan Ince; Enver Yüksel; Emre Aydın
Journal:  Cureus       Date:  2021-12-11

2.  Evaluation of inflammation markers in mitral valve prolapse.

Authors:  Zafer Yalim; İbrahim Ersoy
Journal:  Arch Cardiol Mex       Date:  2022

3.  Monocyte to HDL cholesterol ratio as a marker of the presence and severity of obstructive sleep apnea in hypertensive patients.

Authors:  Min Sun; Chao Liang; Hui Lin; Yuezhi Meng; Qunzhong Tang; Xiaoyu Shi; Erming Zhang; Qiang Tang
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.